Roivant's dermatomyositis drug Lisraya snags FDA approval

The FDA approved Roivant’s dermatomyositis drug brepocitinib on Wednesday, the first major regulatory nod that could usher in a multibillion revenue stream for the hub-and-spoke pharma. The drug, marketed as Lisraya, is the first oral ...